These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 24191589)
1. [Survival analysis and immunohistochemical study of HER-2 and AR (androgen receptor) expression in salivary duct carcinoma]. Otsuka K; Imanishi Y; Habu N; Sato Y; Shigetomi S; Fujii R; Sakamoto K; Tomita T; Fujii M; Kameyama K; Ogawa K Nihon Jibiinkoka Gakkai Kaiho; 2013 Sep; 116(9):1024-32. PubMed ID: 24191589 [TBL] [Abstract][Full Text] [Related]
2. The extent of androgen receptor and HER2 expression allows for targeted therapy in most cases of salivary duct carcinoma: analysis of clinical and histopathological data in a tertiary care center. Mayer M; Wolber P; Prinz J; Jansen L; Esser J; Shabli S; Quaas A; Klußmann JP; Sharma SJ; Nachtsheim L; Arolt C Eur Arch Otorhinolaryngol; 2024 Jul; 281(7):3779-3789. PubMed ID: 38587651 [TBL] [Abstract][Full Text] [Related]
3. Impact of postoperative radiotherapy and HER2/new overexpression in salivary duct carcinoma : A monocentric clinicopathologic analysis. Haderlein M; Scherl C; Semrau S; Lettmaier S; Hecht M; Erber R; Iro H; Fietkau R; Agaimy A Strahlenther Onkol; 2017 Nov; 193(11):961-970. PubMed ID: 28828496 [TBL] [Abstract][Full Text] [Related]
4. Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma. Masubuchi T; Tada Y; Maruya S; Osamura Y; Kamata SE; Miura K; Fushimi C; Takahashi H; Kawakita D; Kishimoto S; Nagao T Int J Clin Oncol; 2015 Feb; 20(1):35-44. PubMed ID: 24553861 [TBL] [Abstract][Full Text] [Related]
5. Clinical Outcomes and Prognostic Factors for Salivary Duct Carcinoma: A Multi-Institutional Analysis of 141 Patients. Otsuka K; Imanishi Y; Tada Y; Kawakita D; Kano S; Tsukahara K; Shimizu A; Ozawa H; Okami K; Sakai A; Sato Y; Ueki Y; Sato Y; Hanazawa T; Chazono H; Ogawa K; Nagao T Ann Surg Oncol; 2016 Jun; 23(6):2038-45. PubMed ID: 26790669 [TBL] [Abstract][Full Text] [Related]
6. Invasive micropapillary salivary duct carcinoma: a distinct histologic variant with biologic significance. Nagao T; Gaffey TA; Visscher DW; Kay PA; Minato H; Serizawa H; Lewis JE Am J Surg Pathol; 2004 Mar; 28(3):319-26. PubMed ID: 15104294 [TBL] [Abstract][Full Text] [Related]
7. A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands. Boon E; Bel M; van Boxtel W; van der Graaf WTA; van Es RJJ; Eerenstein SEJ; Baatenburg de Jong RJ; van den Brekel MWM; van der Velden LA; Witjes MJH; Hoeben A; Willems SM; Bloemena E; Smit LA; Oosting SF; ; Jonker MA; Flucke UE; van Herpen CML Int J Cancer; 2018 Aug; 143(4):758-766. PubMed ID: 29492965 [TBL] [Abstract][Full Text] [Related]
8. Expression of PTEN, Androgen Receptor, HER2/neu, Cytokeratin 5/6, Estrogen Receptor-Beta, HMGA2, and PLAG1 in Salivary Duct Carcinoma. Liang L; Williams MD; Bell D Head Neck Pathol; 2019 Dec; 13(4):529-534. PubMed ID: 30390196 [TBL] [Abstract][Full Text] [Related]
10. Prognostic factors and outcome analysis of salivary duct carcinoma. Han MW; Roh JL; Choi SH; Nam SY; Lee HJ; Cho KJ; Lee SW; Kim SY Auris Nasus Larynx; 2015 Dec; 42(6):472-7. PubMed ID: 26028371 [TBL] [Abstract][Full Text] [Related]
11. Expression of Hormone Receptors and HER-2 in Benign and Malignant Salivary Gland Tumors. Can NT; Lingen MW; Mashek H; McElherne J; Briese R; Fitzpatrick C; van Zante A; Cipriani NA Head Neck Pathol; 2018 Mar; 12(1):95-104. PubMed ID: 28681314 [TBL] [Abstract][Full Text] [Related]
12. Expression pattern of androgen receptor and AR-V7 in androgen-deprivation therapy-naïve salivary duct carcinomas. Yang RK; Zhao P; Lu C; Luo J; Hu R Hum Pathol; 2019 Feb; 84():173-182. PubMed ID: 30267779 [TBL] [Abstract][Full Text] [Related]
13. Low-grade salivary duct carcinoma of the parotid gland: report of a case with immunohistochemical analysis. Kusafuka K; Itoh H; Sugiyama C; Nakajima T Med Mol Morphol; 2010 Sep; 43(3):178-84. PubMed ID: 20857268 [TBL] [Abstract][Full Text] [Related]
14. Prognostic value of PSMA, c-MET and E-cadherin in salivary duct carcinoma. van Boxtel W; Uijen MJM; Verhaegh GW; Willems SM; Jonker MA; ; Schalken JA; van Engen-van Grunsven ICH; van Herpen CML Oral Oncol; 2020 Nov; 110():105018. PubMed ID: 33039794 [TBL] [Abstract][Full Text] [Related]
15. Androgen receptor immunohistochemistry in salivary duct carcinoma: a retrospective study of 188 cases focusing on tumoral heterogeneity and temporal concordance. Xu B; Dogan S; Haroon Al Rasheed MR; Ghossein R; Katabi N Hum Pathol; 2019 Nov; 93():30-36. PubMed ID: 31430492 [TBL] [Abstract][Full Text] [Related]
16. Androgen receptor expression in a Sri Lankan patient cohort with early breast carcinoma. Wijesinghe HD; Wijesinghe GK; Mansoor Z; Vigneshwara S; Fernando J; Gunasekera D; Lokuhetty MDS BMC Womens Health; 2020 Sep; 20(1):206. PubMed ID: 32928183 [TBL] [Abstract][Full Text] [Related]
17. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Jaehne M; Roeser K; Jaekel T; Schepers JD; Albert N; Löning T Cancer; 2005 Jun; 103(12):2526-33. PubMed ID: 15900577 [TBL] [Abstract][Full Text] [Related]
18. Reciprocal and Autonomous Glucocorticoid and Androgen Receptor Activation in Salivary Duct Carcinoma. Mitani Y; Lin SH; Pytynia KB; Ferrarotto R; El-Naggar AK Clin Cancer Res; 2020 Mar; 26(5):1175-1184. PubMed ID: 31772120 [TBL] [Abstract][Full Text] [Related]
19. Salivary Duct Carcinoma and Invasive Ductal Carcinoma of the Breast: A Comparative Immunohistochemical Study. Jalaly JB; Sanati S; Chernock RD; Dibe DG; El-Mofty SK Head Neck Pathol; 2018 Dec; 12(4):488-492. PubMed ID: 29302899 [TBL] [Abstract][Full Text] [Related]
20. Carcinoma ex pleomorphic adenoma of the salivary gland: an immunohistochemical study. Matsubayashi S; Yoshihara T Eur Arch Otorhinolaryngol; 2007 Jul; 264(7):789-95. PubMed ID: 17310348 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]